Patents by Inventor Jimmy Van Wiltenburg
Jimmy Van Wiltenburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884645Abstract: The present invention relates to compounds of formula (1): wherein Q is selected from O or S; R1 is a 5-membered nitrogen-containing heteroaryl group substituted with R6 and optionally further substituted; R2 is an alpha, alpha?-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3 to 7 membered saturated or unsaturated, optionally substituted cyclic group; R5 is independently an optionally substituted C1-C4 alkyl group; and R6 is any group comprising a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: March 1, 2019Date of Patent: January 30, 2024Assignee: INFLAZOME LIMITEDInventors: David Miller, Jimmy Van Wiltenburg, Matthew Cooper
-
Patent number: 11834433Abstract: The present invention relates to compounds of formula (I): comprising a 5-membered nitrogen-containing heteroaryl ring A, wherein the heteroaryl ring A is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring A via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: March 1, 2019Date of Patent: December 5, 2023Assignee: INFLAZOME LIMITEDInventors: David Miller, Jimmy Van Wiltenburg, Matthew Cooper
-
Patent number: 11773058Abstract: The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N, O or S; R1 is —NR3R4, —OR5, —(C?NR6)R7, —(CO)R8, —CN, —N3, a quaternary ammonium group or an optionally substituted heterocycle; R3, R4, R5, R6, R7 and R8 are each independently hydrogen or a saturated or unsaturated, optionally substituted C1-C10 hydrocarbyl group optionally including one or more heteroatoms N, O or S; wherein optionally L and R3, or L and R4, or R3 and R4, or L and R5, or L and R6, or L and R7, or R6 and R7, or L and R8 together with the atom(s) to which they are attached may form a 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic group; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted; provided that the atom of L which is attached to the sulfur atom of the sulfonylurea groupType: GrantFiled: August 15, 2018Date of Patent: October 3, 2023Assignee: INFLAZOME LIMITEDInventors: David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Publication number: 20230037255Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 16, 2022Publication date: February 2, 2023Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON
-
Patent number: 11530200Abstract: The present invention relates to compounds of formula (I), wherein Q is selected from O or S; R1 is a 5- or 6-membered heteroaryl group consisting of one or more carbon atoms, and one or more nitrogen and/or oxygen atoms, and substituted with a monovalent, optionally substituted cycloalkyl, cycloalkenyl or heterocyclic group, wherein the 5- or 6-membered heteroaryl group of R1 may optionally be further substituted; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently an optionally substituted C1-C4 alkyl group.Type: GrantFiled: March 1, 2019Date of Patent: December 20, 2022Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Jimmy Van Wiltenburg
-
Patent number: 11518739Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: August 15, 2018Date of Patent: December 6, 2022Assignee: INFLAZOME LIMITEDInventors: David Miller, Angus Macleod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Patent number: 11465992Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: July 4, 2018Date of Patent: October 11, 2022Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Publication number: 20220289692Abstract: The present invention relates to substituted5-membered nitrogen containing heteroaryl compounds, such as triazole esters, where the heteroaryl ring is further substituted via a linking group such as —NH— with a cyclic group which in turn is substituted at the a-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.Type: ApplicationFiled: September 4, 2020Publication date: September 15, 2022Inventors: David MILLER, Angus MACLEOD, Jonathan SHANNON, Jokin CARRILLO ARREGUI, Diana CASTAGNA, Jimmy VAN WILTENBURG, Jacobus Antonius Joseph DEN HARTOG
-
Patent number: 11390628Abstract: Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.Type: GrantFiled: May 21, 2018Date of Patent: July 19, 2022Assignee: River Stone Biotech LLCInventors: Patrick Roussel, Jimmy Van Wiltenburg, Marco Santella
-
Patent number: 11370776Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: GrantFiled: July 4, 2018Date of Patent: June 28, 2022Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Angus Macleod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
-
Publication number: 20220194923Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which they are attached may form a 3- to 12-membered optionally substituted cyclic group; and R2 is a cyclic group substituted at the position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 12, 2019Publication date: June 23, 2022Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON, Jokin CARRILLO ARREGUI, Jimmy VAN WILTENBURG, Jochem Theodoor VAN HERPT
-
Publication number: 20220163539Abstract: The present invention relates to a binding site of the NLRP3 inflammasome. The present invention further relates to a method of and a compound for use in inhibiting NLRP3 activation and treating a disease, disorder or condition responsive to NLRP3 inhibition. The present invention further relates to a method of reducing cellular or mitochondrial Reactive Oxygen Species (ROS) by inhibiting NLRP3 activation. The present invention further relates to a method of screening a compound to determine the extent of binding of the compound to the binding site of the NLRP3 inflammasome, and to a compound identified by such a screening method.Type: ApplicationFiled: April 11, 2020Publication date: May 26, 2022Applicant: Inflazome LimitedInventors: Matthew COOPER, Angus MACLEOD, Reena HALAI, Jimmy VAN WILTENBURG
-
Publication number: 20220106289Abstract: The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.Type: ApplicationFiled: November 22, 2019Publication date: April 7, 2022Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON, Stephen THOM, Ian STRUTT, Diana CASTAGNA, Jokin CARRILLO ARREGUI, Jimmy VAN WILTENBURG
-
Publication number: 20210380597Abstract: Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.Type: ApplicationFiled: May 21, 2018Publication date: December 9, 2021Inventors: Patrick ROUSSEL, Jimmy VAN WILTENBURG, Marco SANTELLA
-
Publication number: 20210261512Abstract: The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as —NH—, with a cyclic group which in turn is substituted at the ?-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.Type: ApplicationFiled: May 3, 2019Publication date: August 26, 2021Applicant: INFLAZOME LIMITEDInventors: David MILLER, Angus MACLEOD, Stephen THOM, Christopher G. MCPHERSON, Thomas ALANINE, Jokin CARRILLO ARREGUI, Claire-Lise CIANA, Jonathan SHANNON, Jimmy VAN WILTENBURG, Jacobus Antonius Joseph DEN HARTOG
-
Publication number: 20210047302Abstract: The present invention relates to compounds of formula (I), wherein Q is selected from O or S; R1 is a 5- or 6-membered heteroaryl group consisting of one or more carbon atoms, and one or more nitrogen and/or oxygen atoms, and substituted with a monovalent, optionally substituted cycloalkyl, cycloalkenyl or heterocyclic group, wherein the 5- or 6-membered heteroaryl group of R1 may optionally be further substituted; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently an optionally substituted C1-C4 alkyl group.Type: ApplicationFiled: March 1, 2019Publication date: February 18, 2021Applicant: Inflazome LimitedInventors: Matthew COOPER, David MILLER, Jimmy VAN WILTENBURG
-
Publication number: 20210040065Abstract: The present invention relates to compounds of formula (I): comprising a 5-membered nitrogen-containing heteroaryl ring A, wherein the heteroaryl ring A is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring A via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: March 1, 2019Publication date: February 11, 2021Inventors: David MILLER, Jimmy VAN WILTENBURG, Matthew COOPER
-
Publication number: 20210002274Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R2 is a cyclic group substituted at the a and a? positions, wherein the substituent at the ?-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl.Type: ApplicationFiled: March 1, 2019Publication date: January 7, 2021Inventors: Matthew COOPER, David MILLER, Jimmy VAN WILTENBURG, Johannes Wilhem Georg MEISSNER, Jochem Theodoor VAN HERPT, Zhou Min LION, Jonathan SHANNON, Stephen ST-GALLAY
-
Publication number: 20200407340Abstract: The present invention relates to compounds of formula (I): (I) wherein Q is selected from O or S; R1 is an optionally substituted hydrocarbyl group which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, provided that the hydrocarbyl group includes at least one heteroatom N, O or S in its carbon skeleton or is substituted with a substituent comprising at least one heteroatom N, O or S, and provided that the atom of R1 which is attached to the sulfur atom of the remainder of the molecule is not a ring atom of a cyclic group; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHRs or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl.Type: ApplicationFiled: March 1, 2019Publication date: December 31, 2020Inventors: Matthew COOPER, David MILLER, Jimmy VAN WILTENBURG, Jonathan SHANNON, Stephen ST-GALLAY
-
Publication number: 20200399242Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 may optionally be substituted; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHRs or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: March 1, 2019Publication date: December 24, 2020Inventors: David MILLER, Jimmy VAN WILTENBURG, Matthew COOPER